Cara Therapeutics logo
Cara Therapeutics Announces Positive Top-Line Results From Phase 2a Trial of Oral CR845 in Chronic Pain Patients With Osteoarthritis of the Knee or Hip
December 09, 2015 07:00 ET | Cara Therapeutics
Dose-related reduction observed in mean baseline pain score up to 34 percent after two weeks, with statistically significant reduction in mean rescue medication for top 5.0 mg dose All four...
Cara Therapeutics logo
Cara Therapeutics to Present Poster at the ASHP 2015 Midyear Clinical Meeting
December 01, 2015 08:00 ET | Cara Therapeutics
SHELTON, Conn., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics logo
Cara Therapeutics to Webcast Presentation at the Piper Jaffray 27th Annual Healthcare Conference
November 25, 2015 08:00 ET | Cara Therapeutics
SHELTON, Conn., Nov. 25, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics logo
Cara Therapeutics to Webcast Presentation at the Stifel 2015 Healthcare Conference
November 11, 2015 08:00 ET | Cara Therapeutics
SHELTON, Conn., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics logo
Cara Therapeutics Reports Third Quarter 2015 Financial Results
November 09, 2015 16:01 ET | Cara Therapeutics
– Initiated Phase 3 program for I.V. CR845 in acute postoperative pain – – Initiated Phase 2a trial of Oral CR845 in osteoarthritis patients – – Earned $2.75M in...
Cara Therapeutics logo
Cara Therapeutics to Announce Third Quarter 2015 Financial Results on November 9, 2015
November 02, 2015 16:30 ET | Cara Therapeutics
SHELTON, Conn., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics logo
Cara Therapeutics to Present Late-Breaking Poster at Kidney Week 2015
October 29, 2015 08:00 ET | Cara Therapeutics
SHELTON, Conn., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics logo
Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference
October 26, 2015 08:00 ET | Cara Therapeutics
Chief Medical Officer Dr. Joseph Stauffer to discuss potential for kappa opioids SHELTON, Conn., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology...
Cara Therapeutics logo
Cara Therapeutics to Sponsor Symposium and Present Poster at ANESTHESIOLOGY 2015
October 19, 2015 08:00 ET | Cara Therapeutics
Pain experts to discuss trends in kappa opioid receptor agonists and the future of postoperative pain management Company to present positive data from Phase 2 acute pain trials of I.V....
Cara Therapeutics logo
Cara Therapeutics Achieves Milestone Payments From Japan and South Korea Partners for Development of CR845 in Uremic Pruritus
October 13, 2015 08:00 ET | Cara Therapeutics
$2.5M Milestones Earned for Advancement of CR845 in Phase 2 Clinical Trials in U.S. and Japan SHELTON, Conn., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a...